Eli Lilly's acquisition of intellectual property and R&D expenses in the third quarter were $4.57 per share.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.